IBI343 Clinical Trials
5 recruitingDrug
Phase 32Phase 22Phase 12
Showing 1–5 of 5 trials
Recruiting
Phase 1
A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
Locally Advanced Unresectable or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.470 enrolled39 locationsNCT05458219
Recruiting
Phase 2
IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer
Advanced Pancreatic Cancers
Zhejiang University64 enrolled2 locationsNCT06770439
Recruiting
Phase 3
A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma
Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Innovent Biologics (Suzhou) Co. Ltd.450 enrolled22 locationsNCT06238843
Recruiting
Phase 3
A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)
Pancreatic Cancer
Innovent Biologics (Suzhou) Co. Ltd.201 enrolled1 locationNCT07066098
Recruiting
Phase 1Phase 2
IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer
Gastric Cancer
Ruijin Hospital55 enrolled1 locationNCT07025889